Navigation Links
Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis's Gleevec and Tasigna and Bristol-Myers Squibb's Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche's Rituxan and Cephalon's Treanda) until 2015, when patent and orphan-drug exclusivities of key brands will impact the sustainability of this growth.

The new Spectrum report entitled Strategic Overview of Chronic and Acute Leukemias finds that 90 percent of patients respond to receiving Gleevec, presenting it as an ideal model for companies developing targeted leukemia therapies. However, while CML and CLL therapies are predicted to drive the leukemia market, the treatable-pool of chronic and acute leukemia patient populations -- CML, CLL, acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) -- is projected to grow at only low single-digit compound annual growth rates through 2015, which could potentially hamper research and development efforts.

"Patient population size could be considered a constraint to development of new drugs, since if patients are considered on the basis of genetic variants, the potential pool of treatable patients for a particular therapy can be further narrowed," states Matthew Drapeau, analyst with Decision Resources. "In addition, a lack of understanding of the etiology of leukemia is constraining clinical and commercial progress."

In addition to providing a forecast for key leukemia brands in the United States, France, Germany, Italy, Spain, and the United Kingdom, the Strategic Overview of Chronic and Acute Leukemias provides insight on:

  • U.S. hematological-oncologist opinions on diagnosis, current and emerging therapies, treatment decisions and other factors.
  • Leukemia
    '/>"/>

  • SOURCE Decision Resources
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related biology technology :

    1. Sales Contracts Worth $2.3 Million Signed Since 1 July 2008
    2. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
    3. AMDL Inc. Announces Second Quarter 2008 Results; Company Posts $5.8 Million in Sales With a Revenue Increase of 140%
    4. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
    5. InVitria Expands Sales Team
    6. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
    7. Campbell Alliance Sales Practice to Present at CBIs Leadership Summit on Evolving the Pharma Sales Model
    8. BioElectronics Corp Aggressively Expands Sales into Middle East
    9. Genstruct Names Louis Latino VP of Sales
    10. Guillermo Moreno Named Aurillions Vice President of Sales and Marketing
    11. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
    (Date:8/20/2014)... Mass. , Aug. 20, 2014  Decision Resources Group finds ... , Russia , India ... $1.6 billion in 2013, roughly equal to the size of ... however, the BRIC market will experience much faster growth as a ... aging population. Other key findings from Decision Resources Group,s ...
    (Date:8/20/2014)... Stimulating nerves in your ear could improve the health ... at the University of Leeds used a standard TENS ... apply electrical pulses to the tragus, the small raised ... front of the ear canal. , The stimulation changed ... by reducing the nervous signals that can drive failing ...
    (Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
    Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3'Tickling' your ear could be good for your heart 2Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2
    ... 9, 2012 , Collaboration to create ... to active TB, enabling early treatment and disease outbreak prevention ... infectious disease portfolio with development of DNA-/RNA-based test that complements ... , New assay will use whole blood transcription profiling ...
    ... a report published in Nature Physics , they used ... magnetic. Graphene is a sheet of carbon atoms ... it exhibits no signs of the conventional magnetism usually associated ... remarkable properties won Manchester researchers the Nobel Prize in Physics ...
    ... Bioscience announced today that it has secured $47.5 million ... in the financing along with existing investors OrbiMed Advisors, ... with the financing, Josh Bilenker, M.D., Partner at Aisling ... of this round will support commercialization of the company,s ...
    Cached Biology Technology:QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 2QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 3QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 4QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 5QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 6QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection 7Graphene reveals its magnetic personality 2Roka Bioscience Secures $47.5 Million in Series D Financing 2
    (Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
    (Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
    (Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
    Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
    ... projecting how many people will get sick from seasonal ... season. The research, conducted by scientists at the National ... PLoS Currents: Influenza . Building on other ... the Influenza A virus is related to its novelty ...
    ... A team of UCSF researchers has engineered E. coli with ... program cells to communicate and perform computations. The work ... computers and creates a method to create circuits by "rewiring" ... cells into miniature computers, according to findings that will be ...
    ... now submerged beneath the Persian Gulf may have been home ... to an article published today in Current Anthropology ... University of Birmingham in the U.K., says that the area ... host to humans for over 100,000 years before it was ...
    Cached Biology News:Researchers devise computer model for projecting severity of flu season 2UCSF team develops 'logic gates' to program bacteria as computers 2Lost civilization under Persian Gulf? 2
    ...
    Luminometers...
    ... serial preparation of four ... cytosol/particulate/cytoskeleton/nuclear fractions from one ... can directly be used ... as 2-D gel/Western blot/gel-shift/translocation/enzyme ...
    Mouse IL-31 RA Biotinylated Affinity Purified PAb...
    Biology Products: